Therese Lindvall Bark

Therese Lindvall Bark has a diverse work experience in the field of scientific research and development. Therese started their career in 2004 at Lund University as a PhD student, focusing on genetic and immunological studies in animal models of rheumatoid arthritis and multiple sclerosis. During this time, they developed congenic mouse lines with suppressive/enhancing effects for autoimmune diseases.

In 2009, Therese joined Redoxis AB as a Senior Scientist Immunology, where they validated and evaluated animal models of autoimmune diseases. Therese also worked on increasing and improving the in vivo portfolio for these models and conducted planning, preparation, and analysis of in vivo studies.

At Redoxis AB, Therese also served as a Project Leader and was responsible for the development and evaluation of new methods for validating therapies for autoimmune conditions. Therese managed a Eurostars project on MRI in animal models of autoimmunity and handled the writing of ethical permits.

In 2016, Therese worked at ProNoxis AB as a Project Manager, overseeing a pre-clinical Eurostars research project focused on developing small molecule drugs for treating autoimmune diseases. Their responsibilities included project management, experimental design, development, and performing in vivo, ex vivo, and in vitro studies using animal models, cell cultures, and various analytical techniques.

Therese's most recent experience is with BioInvent International AB, where they started in 2017 as a Process Engineer Cell Culture. Therese was responsible for the process development of cell culture with CHO cells/mammalian cells in bioreactors, and they successfully transferred cell bank production and cell culture processes from development to production. In April 2021, they transitioned to the role of Manufacturing Scientist at the same company.

Overall, Therese Lindvall Bark has a strong background in immunology, animal models, cell culture, and project management, with a focus on autoimmune diseases.

Therese Lindvall Bark obtained their first Master of Science (M.Sc.) degree in Biotechnology from The Faculty of Engineering at Lund University, where they studied from 1999 to 2004. Following this, they pursued a Master of Science (M.Sc.) degree at the Biomedical Research school, Lund University for the year 2003-2004. Therese then went on to complete a Doctor of Philosophy (PhD) in Medical Inflammation Research at Lund University from 2004 to 2009.